Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Aug 15;69(5):551-9.
doi: 10.1097/QAI.0000000000000651.

Improving Adherence to Antiretroviral Therapy With Triggered Real-time Text Message Reminders: The China Adherence Through Technology Study

Lora L Sabin  1 , Mary Bachman DeSilva, Christopher J Gill, Li Zhong, Taryn Vian, Wubin Xie, Feng Cheng, Keyi Xu, Guanghua Lan, Jessica E Haberer, David R Bangsberg, Yongzhen Li, Hongyan Lu, Allen L Gifford
Affiliations
Randomized Controlled Trial

Improving Adherence to Antiretroviral Therapy With Triggered Real-time Text Message Reminders: The China Adherence Through Technology Study

Lora L Sabin et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Real-time adherence monitoring is now possible through medication storage devices equipped with cellular technology. We assessed the effect of triggered cell phone reminders and counseling using objective adherence data on antiretroviral therapy (ART) adherence among Chinese HIV-infected patients.

Methods: We provided ART patients in Nanning, China, with a medication device (Wisepill) to monitor their ART adherence electronically. After 3 months, we randomized subjects within optimal (≥95%) and suboptimal (<95%) adherence strata to intervention vs. control arms. In months 4-9, intervention subjects received individualized reminders triggered by late dose taking (no device opening by 30 minutes past dose time) and counseling using device-generated data. Controls received no reminders or data-informed counseling. We compared postintervention proportions achieving optimal adherence, mean adherence, and clinical outcomes.

Results: Of 120 subjects enrolled, 116 (96.7%) completed the trial. Preintervention optimal adherence was similar in intervention vs. control arms (63.5% vs. 58.9%, respectively; P = 0.60). In the last intervention month, 87.3% vs. 51.8% achieved optimal adherence [risk ratio (RR): 1.7, 95% confidence interval (CI): 1.3 to 2.2] and mean adherence was 96.2% vs. 89.1% (P = 0.003). Among preintervention suboptimal adherers, 78.3% vs. 33.3% (RR: 2.4, CI: 1.2 to 4.5) achieved optimal adherence and mean adherence was 93.3% vs. 84.7% (P = 0.039). Proportions were 92.5% and 62.9% among optimal adherers, respectively (RR: 1.5, CI: 1.1 to 1.9) and mean adherence was 97.8% vs. 91.7% (P = 0.028). Postintervention clinical outcomes were not significant.

Conclusions: Real-time reminders significantly improved ART adherence in this population. This approach seems promising for managing HIV and other chronic diseases and warrants further investigation and adaptation in other settings.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

For the remaining authors, no potential conflicts of interest were declared.

Figures

Figure 1
Figure 1
Study profile
Figure 2
Figure 2
Monthly mean adherence among intervention and control subjects, stratified by pre-intervention period optimal (≥95%) or suboptimal (<95%) adherence, using an on-time adherence measure Note: Pre-intervention period refers to Months 1–3; intervention period is the subsequent 6-month period (Months 4–9) during which subjects received triggered reminders and data-informed counseling.
Figure 3
Figure 3
Comparison of ‘Late Dose Behavior’ by period and randomization arms Note: Pre-intervention period refers to Months 1–3; intervention period is the subsequent 6-month period during which subjects received triggered reminders. The figure indicates the proportion of ‘late doses’ (those not taken by 30 minutes after scheduled dose time) that were subsequently taken ‘on time’ (within the next 30 minutes).
See this image and copyright information in PMC

References

    1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS; 2013.
    1. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105–110. - PubMed
    1. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–1183. - PubMed
    1. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–1058. - PubMed
    1. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78–84. - PubMed

Publication types

Substances